{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:35:17Z","timestamp":1793039717189,"version":"4.5.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi250556-4\"><jats:title>Importance<\/jats:title><jats:p>Ovarian cancer, often diagnosed at advanced stages, presents significant challenges in treatment and survival. Evaluation of different hyperthermic intraperitoneal chemotherapy (HIPEC) regimens could provide crucial insights to improve patient outcomes.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250556-5\"><jats:title>Objective<\/jats:title><jats:p>To evaluate whether HIPEC with paclitaxel (HIPEC-paclitaxel) is associated with similar oncological outcomes as HIPEC with cisplatin (HIPEC-cisplatin) in patients with advanced ovarian cancer undergoing interval cytoreductive surgery (iCRS).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250556-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This multicenter retrospective cohort study included patients with advanced ovarian cancer who received iCRS and HIPEC. Patients with primary or secondary surgical procedures or nonovarian cancers were excluded. Data came from the National Registry of Peritoneal Carcinomatosis, which includes 27 Spanish specialized peritoneal oncology centers. Cases were included from January 2012 to December 2022. The study used propensity score matching to balance the groups and ensure comparability.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250556-7\"><jats:title>Exposure<\/jats:title><jats:p>HIPEC-cisplatin and HIPEC-paclitaxel, administered during iCRS. The HIPEC regimen was selected based on the standard clinical protocol for advanced ovarian cancer.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250556-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end points were overall survival (OS) and disease-free survival (DFS). The secondary end point was the rate of complications in each group. These outcomes were predefined prior to data collection.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250556-9\"><jats:title>Results<\/jats:title><jats:p>A total of 846 patients (mean [SD] age, 59.04 [11.01] years) were included (325 [38.4%] in HIPEC-cisplatin group; 521 [61.6%] in HIPEC-paclitaxel group), and 199 patients in each group were propensity score matched. Among these 398 matched patients, the HIPEC-paclitaxel group had similar DFS and OS compared with the HIPEC-cisplatin group. Additionally, similar morbidity was observed. Equivalence in OS and DFS was observed during the initial 20 and 15 months of follow-up, respectively, with an equivalence margin of 0.1 respectively.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250556-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this cohort study of patients with advanced ovarian cancer, HIPEC-paclitaxel was associated with comparable oncologic outcomes as HIPEC-cisplatin, suggesting that it could be a viable alternative. These findings support its use, especially in patients in whom cisplatin could be contraindicated. Further studies may help refine treatment protocols and improve patient-specific outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.17676","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T15:31:09Z","timestamp":1750951869000},"page":"e2517676","source":"Crossref","is-referenced-by-count":5,"title":["Interval Cytoreductive Surgery and Cisplatin- or Paclitaxel-Based HIPEC for Advanced Ovarian Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Salud","family":"Gonz\u00e1lez S\u00e1nchez","sequence":"first","affiliation":[{"name":"Unit of Surgical Oncology, Reina Sofia University Hospital, Cordoba, Spain"},{"name":"GE09 Research in Peritoneal and Retroperitoneal Oncologic Surgery Group, Maimonides Biomedical Research Institute of Cordoba, Reina Sof\u00eda University Hospital, University of Cordoba, C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Garc\u00eda Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Unit of Gynecology, Reina Sofia University Hospital, Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Antonio","family":"Cascales-Campos","sequence":"additional","affiliation":[{"name":"Peritoneal Surface Malignancy Unit, Department of Surgery Clinic and University Hospital \u201cVirgen de la Arrixaca,\u201d University of Murcia, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alida","family":"Gonzalez Gil","sequence":"additional","affiliation":[{"name":"Peritoneal Surface Malignancy Unit, Department of Surgery Clinic and University Hospital \u201cVirgen de la Arrixaca,\u201d University of Murcia, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Manzanedo","sequence":"additional","affiliation":[{"name":"Peritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, Fuenlabrada University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Pereira Perez","sequence":"additional","affiliation":[{"name":"Peritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, Fuenlabrada University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"D\u00edaz G\u00f3mez","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology Peritoneal and Retroperitoneal, Virgen del Rocio University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Gonz\u00e1lez-de Pedro","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology Peritoneal and Retroperitoneal, Virgen del Rocio University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Asensio Diaz","sequence":"additional","affiliation":[{"name":"Advanced Oncologic Surgery Unit, Department of General and Digestive Surgery, Hospital R\u00edo Hortega, Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pacheco Sanchez","sequence":"additional","affiliation":[{"name":"Advanced Oncologic Surgery Unit, Department of General and Digestive Surgery, Hospital R\u00edo Hortega, Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aranzazu","family":"Prada-Villaverde","sequence":"additional","affiliation":[{"name":"Department of HBP and Liver Transplant Surgery, Badajoz University Hospital, Badajoz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Ja\u00e9n Torrejimeno","sequence":"additional","affiliation":[{"name":"Department of HBP and Liver Transplant Surgery, Badajoz University Hospital, Badajoz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Lacueva","sequence":"additional","affiliation":[{"name":"Oncological Abdominal and Pelvic Surgery Unit, Department of General Surgery, University General Hospital of Elche, Elche, Spain"},{"name":"Department Pathology and Surgery, Miguel Hern\u00e1ndez University, San Juan de Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iban","family":"Caravaca-Garcia","sequence":"additional","affiliation":[{"name":"Oncological Abdominal and Pelvic Surgery Unit, Department of General Surgery, University General Hospital of Elche, Elche, Spain"},{"name":"Department Pathology and Surgery, Miguel Hern\u00e1ndez University, San Juan de Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Torres-Melero","sequence":"additional","affiliation":[{"name":"Department of General and Digestive Surgery, Torrecardenas University Hospital, Almer\u00eda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Sanchez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology, University Hospital Ciudad Real, Ciudad Real, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"D\u00edaz Reques","sequence":"additional","affiliation":[{"name":"Unit of Surgery, Hospital San Chinarro, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Ram\u00edrez Plaza","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology, Hospital Quiron, Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Guti\u00e9rrez-Calvo","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology, University Hospital Principe de Asturias, Alcala Henares, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Gonz\u00e1lez Bay\u00f3n","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology, University Hospital Gregorio Mara\u00f1on, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Morales-Soriano","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology, University Hospital Son Espases, Palma de Mallorca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"L\u00f3pez-Mozos","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology, University Hospital Clinic of Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Bjelic","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology, Hospital Moises Broggi, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Galindo \u00c1lvarez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, Insititute Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS) Ramon y Cajal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Emilio","family":"Marcello Fernandez","sequence":"additional","affiliation":[{"name":"University Hospital Alcorcon Foundation, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrella","family":"Turienzo Santos","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology, University Hospital Central Asturias, Asturias, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Titos Garc\u00eda","sequence":"additional","affiliation":[{"name":"Unit of Surgery, University Hospital Regional Malaga, Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"\u00c1lvarez Seoane","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology, University Hospital La Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Artiles Armas","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology, Hospital Negrin Las Palmas de Gran Canaria, Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio Terol","family":"Garaulet","sequence":"additional","affiliation":[{"name":"Unit of Peritoneal Surgery, University General Reina Sofia Hospital, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Villarejo Campos","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology, University Hospital Fundacion Jimenez Diaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Bold\u00f3 Roda","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology, Hospital Provincial Castellon, Castell\u00f3, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rihuete Caro","sequence":"additional","affiliation":[{"name":"Unit of Surgery, Infanta Elena University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Garc\u00eda Fadrique","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology, Oncologic Valencia Institute, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Arjona-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology, Reina Sofia University Hospital, Cordoba, Spain"},{"name":"GE09 Research in Peritoneal and Retroperitoneal Oncologic Surgery Group, Maimonides Biomedical Research Institute of Cordoba, Reina Sof\u00eda University Hospital, University of Cordoba, C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"REGECOP collaborators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Lozano-Lominchar","sequence":"additional","affiliation":[{"name":"for the REGECOP collaborators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenceslao","family":"Vasquez","sequence":"additional","affiliation":[{"name":"for the REGECOP collaborators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gil-Gomez","sequence":"additional","affiliation":[{"name":"for the REGECOP collaborators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Granados","sequence":"additional","affiliation":[{"name":"for the REGECOP collaborators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari Carmen","family":"Vazquez-Borrego","sequence":"additional","affiliation":[{"name":"for the REGECOP collaborators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Casado-Adam","sequence":"additional","affiliation":[{"name":"for the REGECOP collaborators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Rodriguez Ort\u00edz","sequence":"additional","affiliation":[{"name":"for the REGECOP collaborators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Rufian","sequence":"additional","affiliation":[{"name":"for the REGECOP collaborators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"for the REGECOP collaborators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"issue":"3","key":"zoi250556r1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"zoi250556r2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage.","volume":"111","author":"Peres","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"zoi250556r3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"issue":"9990","key":"zoi250556r4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"zoi250556r5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2020.02.020","article-title":"Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers in phase III randomised trial.","volume":"130","author":"Onda","year":"2020","journal-title":"Eur J Cancer"},{"issue":"11","key":"zoi250556r6","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"zoi250556r7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250556r8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer.","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi250556r9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial.","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg"},{"issue":"4","key":"zoi250556r10","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","article-title":"Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial.","volume":"29","author":"Antonio","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"zoi250556r11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.bulcan.2023.02.011","article-title":"Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer.","volume":"111","author":"Harter","year":"2024","journal-title":"Bull Cancer"},{"issue":"19","key":"zoi250556r12","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.3390\/jcm11195785","article-title":"The role of intraperitoneal intraoperative chemotherapy with paclitaxel in the surgical treatment of peritoneal carcinomatosis from ovarian cancer-hyperthermia versus normothermia: a randomized controlled trial.","volume":"11","author":"Casado-Adam","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"zoi250556r13","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/curroncol31020048","article-title":"Paclitaxel as HIPEC-drug after surgical cytoreduction for ovarian peritoneal metastases: a randomized phase III clinical trial (HIPECOVA).","volume":"31","author":"Villarejo Campos","year":"2024","journal-title":"Curr Oncol"},{"key":"zoi250556r14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.suronc.2020.09.019","article-title":"HIPEC plus EPIC paclitaxel for maximal perioperative treatments of advanced epithelial ovarian cancer. Long-term results of a pilot study.","volume":"35","author":"Sugarbaker","year":"2020","journal-title":"Surg Oncol"},{"key":"zoi250556r16","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1007\/s002800051093","article-title":"Successful management of microscopic residual disease in large bowel cancer.","volume":"43","author":"Sugarbaker","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3\u20134","key":"zoi250556r17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity scores to help design observational studies: application to the tobacco litigation.","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Serv Outcomes Res Methodol"},{"issue":"1","key":"zoi250556r18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","article-title":"Constructing a control group using multivariate matched sampling methods that incorporate the propensity score.","volume":"39","author":"Rosenbaum","year":"1985","journal-title":"Am Stat"},{"issue":"1","key":"zoi250556r19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer.","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi250556r20","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.","volume":"24","author":"Aronson","year":"2023","journal-title":"Lancet Oncol"},{"issue":"9","key":"zoi250556r21","doi-asserted-by":"publisher","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","article-title":"NCCN Guidelines Insights: ovarian cancer, version 3.2022 (J).","volume":"20","author":"Armstrong","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"27","key":"zoi250556r22","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/JCO.19.00091","article-title":"Is there a role for intraperitoneal chemotherapy, including HIPEC, in the management of ovarian cancer?","volume":"37","author":"Vergote","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi250556r23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13048-024-01468-3","article-title":"The impact of paclitaxel-based hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer patients\u2014interim analysis of safety and immediate efficacy of a randomized control trial (C-HOC trial).","volume":"17","author":"Wang","year":"2024","journal-title":"J Ovarian Res"},{"issue":"19","key":"zoi250556r24","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.3390\/jcm11195785","article-title":"The role of intraperitoneal intraoperative chemotherapy with paclitaxel in the surgical treatment of peritoneal carcinomatosis form ovarian cancer\u2014hyperthermia versus normothermia: a randomized controlled trial.","volume":"11","author":"Casado-Adam","year":"2022","journal-title":"J Clin Med"},{"issue":"8","key":"zoi250556r25","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.ejso.2023.03.214","article-title":"Peritoneal metastasis of advanced epithelial ovarian carcinoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a retrospective international multicentric data analysis.","volume":"49","author":"Torun","year":"2023","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"zoi250556r26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.suronc.2016.05.010","article-title":"Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C\/IV ovarian cancer: is there any difference?","volume":"25","author":"Cascales-Campos","year":"2016","journal-title":"Surg Oncol"},{"key":"zoi250556r15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume-title":"Peritoneal Carcinomatosis: Principles of Management","author":"Jacquet","year":"1996"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2835694\/gonzlez_snchez_2025_oi_250556_1750269377.69859.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T15:31:10Z","timestamp":1750951870000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2835694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.17676","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]}}}